PRF + Minocycline vs Arestin in Non-surgical Perio Therapy

Platelet-rich Fibrin With Minocycline Versus Arestin in Non-surgical Periodontal Therapy: A Split-Mouth Randomized Controlled Clinical Trial

Periodontitis is a chronic, biofilm-modulated inflammatory disease characterized by microbial dysbiosis and a dysregulated host immune response, eventually resulting in the gradual breakdown of the periodontal attachment apparatus. While non-surgical periodontal therapy (NSPT) remains the first choice of treatment, its capability to completely resolve inflammation and pocketing in moderate disease severity may be limited, supporting the use of adjunctive antimicrobial or biologic interventions. Platelet-rich fibrin (PRF) and locally administered antibiotics, including minocycline, have individually shown clinical advantages; nonetheless, evidence assessing their combined utility remains unexplored. This split-mouth randomized controlled clinical trial (RCT) aims to compare the clinical efficacy of PRF combined with minocycline versus minocycline microspheres hydrochloride (Arestin) as adjuncts to NSPT in patients with Stage II or III, Grade A or B periodontitis.

Study Overview

• Status: Completed
• Conditions: Non-surgical Periodontal Therapy
• Intervention / Treatment: Drug: Arestin; Biological: PRF + M

Detailed Description

Periodontitis is a chronic, biofilm-modulated inflammatory disease characterized by microbial dysbiosis and a dysregulated host immune response, eventually resulting in the gradual breakdown of the periodontal attachment apparatus. While non-surgical periodontal therapy (NSPT) remains the first choice of treatment, its capability to completely resolve inflammation and pocketing in moderate disease severity may be limited, supporting the use of adjunctive antimicrobial or biologic interventions. Platelet-rich fibrin (PRF) and locally administered antibiotics, including minocycline, have individually shown clinical advantages; nonetheless, evidence assessing their combined utility remains unexplored. This split-mouth randomized controlled clinical trial (RCT) aims to compare the clinical efficacy of PRF combined with minocycline versus minocycline microspheres hydrochloride (Arestin) as adjuncts to NSPT in patients with Stage II or III, Grade A or B periodontitis.

• Study Type: Interventional
• Enrollment (Actual): 15
• Phase: Phase 4

Contacts and Locations

Study Locations

• United States
  • Florida
    • Sarasota, Florida, United States, 34240
      • Lakewood Ranch Dental

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Male and Female subjects requiring non-surgical periodontal therapy• No contraindications to periodontal treatment

Exclusion Criteria:

• previous periodontal treatment within the past 6 months;
• local or systemic antibiotic treatment within the past 3 months;
• diagnosis of Stage I/ or IV periodontitis;
• poor oral hygiene defined as a full-mouth plaque score >30%;
• history of radiation or immunosuppressive therapy;
• presence of neurologic disorders, major mechanical obstruction to mouth opening, or acute temporomandibular capsulitis;
• systemic conditions that may compromise bone metabolism or wound healing such as metabolic bone disease, uncontrolled diabetes;
• history of substance abuse such as drug or alcohol; or
• current pregnancy, nursing, or planning pregnancy during the study period.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Single

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Arestin Group; Arestin placed interproximal sites after non-surgical therapy	Drug: Arestin; Arestin evaluated as an adjunct to non-surgical therapy
Active Comparator: PRF + M Group; PRF with Minocycline placed interproximal sites after non-surgical therapy	Biological: PRF + M; PRF with Minocycline evaluated as an adjunct to non-surgical therapy

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Clinical Attachment Loss	Clinical Attachment Loss was measured utilizing a periodontal probe at six sites per tooth.	6 months
Probing Depths	Probing depths were recorded utilizing a periodontal probe at six sites per tooth.	6 months
Gingival Recession	Gingival Recession was measured utilizing a periodontal probe at six sites per tooth.	6 months

Collaborators and Investigators

• Sponsor: Center for Advanced Rejuvenation and Esthetics

Study record dates

Study Major Dates

• Study Start (Actual): December 1, 2024
• Primary Completion (Actual): December 1, 2025
• Study Completion (Actual): December 30, 2025

Study Registration Dates

• First Submitted: February 22, 2026
• First Submitted That Met QC Criteria: February 22, 2026
• First Posted (Actual): February 27, 2026

Study Record Updates

• Last Update Posted (Actual): May 28, 2026
• Last Update Submitted That Met QC Criteria: May 24, 2026
• Last Verified: May 1, 2026

More Information

Terms related to this study

• Keywords: PRF; Minocycline; Non-surgical periodontal therapy; Platelet-rich Fibrin
• Additional Relevant MeSH Terms: cyclopia sequence; Hormones; Hormones, Hormone Substitutes, and Hormone Antagonists; Hypothalamic Hormones; Peptide Hormones; Neuropeptides; Peptides; Amino Acids, Peptides, and Proteins; Nerve Tissue Proteins; Proteins; Organic Chemicals; Hydrocarbons; Hydrocarbons, Cyclic; Polycyclic Aromatic Hydrocarbons; Hydrocarbons, Aromatic; Polycyclic Compounds; Naphthacenes; Tetracyclines; Minocycline; Prolactin-Releasing Hormone
• Other Study ID Numbers: 12625-NEstrin

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Data will be shared upon request
• IPD Sharing Time Frame: Beginning 3 months and ending 3 years after the publication of the results
• IPD Sharing Access Criteria: Data will be provided to researchers conducting a meta-analysis
• IPD Sharing Supporting Information Type: STUDY_PROTOCOL; SAP; CSR

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: Yes
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: Yes